SEAGULL HEALTH
Your health,We care!
Vebreltinib Enteric Capsules is the only First-in-class targeted drug in China that simultaneously covers three indications: MET exon 14 skipping mutation, MET amplification non-small cell lung cancer, and glioma.
AuthenticGuaranteeFast DeliveryPrivacy In November 2023, the National Medical Products Administration (NMPA)
approved vebreltinib (Wanbirui) for the treatment of adult patients with locally
advanced or metastatic non-small cell lung cancer (NSCLC) harboring
Mesenchymal-Epithelial Transition (MET) exon 14 skipping mutation.
In April 2024, the NMPA granted approval of vebrelitinib (Wanbirui) for adult
patients with IDH-mutant astrocytoma (WHO grade 4) or glioblastoma with a
history of lower-grade disease that is positive for the PTPRZ1-MET fusion gene
and has failed prior therapy.
In June 2025, the NMPA approved vebrelitinib (Wanbirui) for the treatment of
adult patients with locally advanced or metastatic non-small cell lung cancer
(NSCLC) with Mesenchymal-Epithelial Transition (MET) amplification.
On June 30, 2025, vebreltinib enteric-coated capsules (brand name: Wanbirui, vebreltinib), a MET inhibitor independently developed by Beijing Purinno ···【Read More】
Update: 04 Feb,2026Source: Haiou HealthViews: 94
On April 23, 2024, the National Medical Products Administration (NMPA) of China formally approved Vebreltinib Enteric-coated Capsules (brand name: Wan···【Read More】
Update: 04 Feb,2026Source: Haiou HealthViews: 90
On November 16, 2023, the National Medical Products Administration (NMPA) released an announcement approving Vebreltinib Enteric-Coated Capsules (trad···【Read More】
Update: 04 Feb,2026Source: Haiou HealthViews: 91
Copyright 2024 @ haiouhealth.com All right reserved SEAGULL HEALTH
